知镜 Cognispect · 医学文献与研究工作台

EphA4 Mediates Protumoral and Antitumoral Effects through Upstream Negative Regulation of AKT in Head and Neck Squamous Cell Carcinoma.

Corbo S, Abdelazeem KNM, Nguyen D, Bhatia S, Van Court B, Olimpo NA, Gadwa J, Hodgson CA, Beynor JI, Samedi VG, Sanz-Garcia E, Siu LL, Saviola AJ, Heasley LE, Pasquale EB, Knitz MW, Karam SD.
Cancer immunology research · 2026-11-01 · PMID 42644611

文献摘要

Head and neck squamous cell carcinoma (HNSCC) is driven by an immunosuppressive tumor microenvironment (TME). We examined the immunomodulatory role of EphA4 in HNSCC using spatial analysis, multicompartment RNA sequencing from oral cavity squamous cell carcinoma, and three genetically engineered mouse models. Within the HNSCC TME, EphA4 is primarily expressed in regulatory T cells (Treg), macrophages, CD8+ T cells, and HNSCC cancer cells. EphA4 in Tregs promotes tumor growth, whereas EphA4 in myeloid cells, CD8+ T cells, and cancer cells limits it. EphA4 mediates these differential effects through shared negative regulation of AKT signaling where its knockout increases AKT activation, leading to reduced Treg immunosuppression, increased M2 macrophage polarization, impaired CD8+ T-cell memory differentiation, and enhanced cancer cell proliferation. APY-d3-PEG4, an EphA4 inhibitor, reduced tumor growth primarily by targeting Tregs. EphA4 expression on CD8+ T cells correlates with treatment response, representing a potential biomarker, and cell type-specific targeting via cis-bispecific antibodies offers a promising therapeutic strategy. Interrogating human data show that EphA4 expression on CD8 correlates to response to treatment, posing it as a potential biomarker for future studies. Mechanistically, our data show EphA4 inhibits AKT signaling, and its inhibition enhances AKT functionality across cell types, yielding opposing effects in cancer.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。